Little TJ, Isaacs NJ, Young RL, Ott R, Nguyen NQ, Rayner CK, Horowitz M, Feinle-Bisset C. Characterization of duodenal expression and localization of fatty acid-sensing receptors in humans: relationships with body mass index. Am J Physiol Gastrointest Liver Physiol 307: G958 -G967, 2014. First published September 25, 2014 doi:10.1152/ajpgi.00134.2014 stimulate the secretion of gastrointestinal hormones, including cholecystokinin (CCK) and glucagon like peptide-1 (GLP-1), which suppress energy intake. In obesity, gastrointestinal responses to FAs are attenuated. Recent studies have identified a key role for the FA-sensing receptors cluster of differentiation (CD)36, G protein-coupled receptor (GPR)40, GPR120, and GPR119 in mediating gastrointestinal hormone secretion. This study aimed to determine the expression and localization of these receptors in the duodenum of humans and to examine relationships with obesity. Duodenal mucosal biopsies were collected from nine lean [body mass index (BMI): 22 Ϯ 1 kg/m 2 ], six overweight (BMI: 28 Ϯ 1 kg/m 2 ), and seven obese (BMI: 49 Ϯ 5 kg/m 2 ) participants. Absolute levels of receptor transcripts were quantified using RT-PCR, while immunohistochemistry was used for localization. Transcripts were expressed in the duodenum of lean, overweight, and obese individuals with abundance of CD36ϾϾGPR40ϾGPR120ϾGPR119. Expression levels of GPR120 (r ϭ 0.46, P ϭ 0.03) and CD36 (r ϭ 0.69, P ϭ 0.0004) were directly correlated with BMI. There was an inverse correlation between expression of GPR119 with BMI (r 2 ϭ 0.26, P ϭ 0.016). Immunolabeling studies localized CD36 to the brush border membrane of the duodenal mucosa and GPR40, GPR120, and GPR119 to enteroendocrine cells. The number of cells immunolabeled with CCK (r ϭ Ϫ0.54, P ϭ 0.03) and GLP-1 (r ϭ Ϫ0.49, P ϭ 0.045) was inversely correlated with BMI, such that duodenal CCK and GLP-1 cell density decreased with increasing BMI. In conclusion, CD36, GPR40, GPR120, and GPR119 are expressed in the human duodenum. Transcript levels of duodenal FA receptors and enteroendocrine cell density are altered with increasing BMI, suggesting that these changes may underlie decreased gastrointestinal hormone responses to fat and impaired energy intake regulation in obesity.
OBESITY, ONE OF THE MOST IMPORTANT public health problems globally, is strongly linked to the consumption of a high-fat diet (11, 21, 25) and is extremely resistant to behavioral intervention (37) . Furthermore, current pharmacological approaches targeted predominately at appetite control in the central nervous system have limited efficacy and/or unacceptable adverse effects. The gastrointestinal (GI) hormones, including cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), and peptide YY (PYY), released from the small intestine in response to nutrients, play a major role in the regulation of energy intake (22) , and fatty acids (FAs), with a chain length Ն12 carbon atoms, are potent stimuli for GI hormone secretion and the suppression of food intake in healthy humans (7, 8) . It has recently been recognized that specific FA-sensing receptors expressed in the small intestine play an important role in mediating the release of GI hormones in response to dietary FAs (22) . Thus targeting the initiation of these satiety signals within the GI tract may be an attractive, and novel, option for the prevention and management of obesity.
There is limited information about the expression and/or localization of FA-sensing receptors in human small intestine; this is a major issue, since there may be differences between humans and animals. In animal and cell-line models, the FA-sensing G protein-coupled receptors (GPRs) GPR40 (6), GPR120 (14, 35) , and GPR119 (17) are expressed on enteroendocrine cells (EECs), and activation of these receptors by FAs with an acyl chain length of Ն12 carbons, or their derivatives, such as oleoylethanolamine (OEA; a FA-derived mediator shown to suppress food intake in animals; Ref. 9) , appears to mediate FA-induced GI hormone secretion (23) . GPR119 plays a key role in sensing the presence of FA-derived mediators in the small intestine. For example, ileal perfusion with OEA in rats is known to trigger GLP-1 release, while the ability of OEA to trigger GLP-1 release from mouse intestinal GLUTag cells is abolished by GPR119-specific small interfering RNA (18) . The receptor-like glycoprotein CD36 expressed on enterocytes predominantly in the proximal small intestine (3) plays an important role in small intestinal fat absorption, facilitating transport of FAs across the cell membrane (24, 30) , and is also critical for the mobilization of OEA. Recently, CD36 has also been found to be important in the mediation of CCK secretion in response to intestinal fat (34) . To date, the localization of these FA-sensing receptors in the duodenum of humans has not been quantified specifically nor are there any studies evaluating whether their expression is altered in disease states, such as obesity.
There is increasing evidence that obesity is characterized by compromised sensing and signaling of ingested nutrients in the GI tract. For example, postprandial plasma GLP-1 (28) and PYY (19) concentrations have been reported to be diminished in obesity. Furthermore, we have recently shown that the stimulation of pyloric motility and plasma CCK in response to intraduodenal oleic acid (C18:1) infusion is attenuated in obese, when compared with lean, individuals (33) . This reduction in GI sensitivity was associated with reduced suppression of subsequent energy intake by C18:1, as well as higher habitual energy and fat intakes (33) . Animal studies have demonstrated that such changes in GI nutrient sensitivity are driven by consumption of a high-fat diet (4). High-fat dietinduced obese rats exhibit decreased protein expression of CCK, GLP-1, and PYY and increased mRNA and protein expression of GPR40 and GPR120 in the proximal small intestine (5) . Taken together, these observations indicate that small intestinal sensing and signaling of FAs are compromised in obesity and contribute to disordered regulation of energy intake. Whether such changes in GI function may be mediated by altered expression and/or function of specific FA-sensing receptors and gut hormones in the small intestine in human obesity is hitherto unknown.
Therefore, the aims of the current study were 1) to evaluate mRNA expression [by quantitative reverse-transcription polymerase chain reaction (qRT-PCR)] and localization (by singleand dual-label immunohistochemistry) of the FA-sensing molecules CD36, GPR40, GPR120, and GPR119 in the duodenum of humans; and 2) to evaluate relationships of FA-receptor expression with body mass index (BMI), as well as with habitual dietary energy and fat intakes. We evaluated expression in the duodenum since this is a key site of nutrient sensing and absorption in humans.
SUBJECTS AND METHODS

Ethics Statement
The study was approved by the Human Research Ethics Committee of the Royal Adelaide Hospital, and all experiments were executed in accordance with The Declaration of Helsinki, as revised in 2000. Each individual provided written, informed, consent before the commencement of the study. The trial was registered with the Australian and New Zealand Clinical Trials Registry (Trial No.: ACTRN12611000390987).
Endoscopy and Collection of Duodenal Mucosal Biopsies
From June 2011 to June 2012, we identified patients meeting our inclusion criteria from clinical notes of consecutive patients attending the Gastrointestinal Investigation Unit, Royal Adelaide Hospital for endoscopy for diagnostic or research (n ϭ 7 obese) purposes. Patients were approached on the morning of their endoscopy to take part in the study. Nine lean (4 male, 5 female, age: 54 Ϯ 6 yr, BMI: 22 Ϯ 1 kg/m 2 ), six overweight (3 male, 3 female, age: 57 Ϯ 7 yr, BMI: 28 Ϯ 1 kg/m 2 ), and seven obese (1 male, 6 female, age: 43 Ϯ 5 yr, BMI: 49 Ϯ 5 kg/m 2 ) Caucasian participants agreed to take part in the study. Exclusion criteria were diffuse mucosal disease involving the upper GI tract, including Crohn's disease and celiac disease, diabetes, and disorders or use of drugs associated with increased bleeding risk (e.g., aspirin, clopidogrel), and Ͼ3 kg weight loss or gain in the last 3 mo. At endoscopy, all patients had macroscopically normal small intestinal mucosa.
Four mucosal biopsies were collected from the second part of the duodenum. Two biopsies were transferred immediately into the RNA stabilization agent RNAlater (Qiagen, Sydney, NSW, Australia) and frozen at Ϫ80°C, and two were fixed in 4% neutral buffered paraformaldehyde at room temperature for 2 h and then briefly dried on a paper towel, before cryoprotection in 30% sucrose, dissolved in 0.1 M phosphate-buffered saline (PBS, pH 7.4), at 4°C overnight. Subsequently, comparative molecular qRT-PCR and immunohistochemical studies were performed as described below.
RNA Extraction
Frozen duodenal mucosal biopsies were transferred into TissueLyser tubes (Qiagen), disrupted by high-speed shaking with one metal bead (TissueLyser LT; Qiagen) and then homogenized in QIAshredder columns (Qiagen). Total cellular RNA was isolated using the RNeasy Mini Kit (Qiagen), as per manufacturer's specifications, which included an on-column DNase digestion. Eluted RNA was then diluted 1:50 in Tris-EDTA buffer, quantified in triplicate by spectrophotometry (260 nm), and assessed for purity using the A 260 /A 280 ratio.
Primers and the Generation of RT-PCR Products for Target Gene Standard Curves
Validated human primers were purchased as QuantiTect primer assays (Qiagen) or designed using NetPrimer software (Premier Biosoft) based on target sequences obtained from the National Center for Biotechnology Information Nucleotide (NCBI) Database (Table 1) . Primers were designed so that at least one of the pair spanned an exon-exon boundary, and were checked for specificity using the NCBI GenBank database. Additional human primers were designed to amplify target genes outside the regions detected by the qRT-PCR primers (Table 2 ) to create absolute standard curves.
Generation of Standard cDNA for CD36, GPR40, GPR120, and GPR119
Absolute standard curves were generated by performing qRT-PCR using the human primers described in Table 2 was run to generate a melt curve from 60 -95°for verification of product specificity, and no primer dimers were observed. This was followed by gel electrophoresis and extraction of cDNA from bands corresponding to the correct molecular product size, for each of the gene targets, using the Ultraclean 15 DNA Purification Kit (MO BIO Laboratories, West Carlsbad, CA). Purified cDNA was subsequently resuspended in TE buffer and concentrations measured in triplicate using a spectrophotometer. The cDNA concentration was converted into copy number based on the formula for the generation of standard curves (1) . Briefly, the mass (m) of a single cDNA molecule was calculated by multiplying the basepair length of the cDNA template (Table  2 ) by a factor derived from the multiplication of Avogadro's constant [6.023 ϫ 10 23 molecules (bp) mol Ϫ1 ] with the average molecular mass of a double-stranded DNA molecule (660 g/mol). Concentrations corresponding to a desired copy number were obtained by the following formula.
Ϫ21 ͒ ϫ copy number reaction volume ͑ l ͒ Stock of the purified cDNA fragments was diluted, and 10-l aliquots of standard cDNA (10 8 copy numbers) were prepared and frozen at Ϫ80°C until RT-PCR was performed. For the generation of standard curves, 1:10 serial dilutions were used, whereby the copy numbers ranged from 10 7 to 10 2 for all GPR targets, and from 10 8 to 10 4 for CD36.
Quantification of Gene Expression by RT-PCR
qRT-PCRs were performed using the conditions described above for generation of standard cDNA but using a 7500 Fast Real-Time PCR system (Applied Biosystems). Sizes of amplified products were confirmed by 3% agarose gel electrophoresis and ethidium bromide staining. Each assay was performed in triplicate and included controls, where the RNA template was replaced with RNase-free water (no template), and where the reverse transcription step was omitted.
For each plate, a series of six dilutions of cDNA standards were prepared, as described above. Each reaction contained 12.5 l of MasterMix, 7.5 l RNase-free water, 2.5 l primer pairs (Table 1) , and 2.5 l of either cDNA standard or patient RNA. The cDNA standards were inserted into the instrument after the reverse transcription step (50°C for 30 min) to generate a template for standard curve generation. The 7500 software automatically generated a standard curve based on the copy numbers of the known standards and the threshold cycle (C T ). The mRNA copy number was calculated by the software from C T values in reference to the standard curve. All replicates were averaged for final mRNA copy number, which was expressed as copies per 25 ng of total RNA of the sample.
Double-Label Immunohistochemistry
After cryoprotection with 30% sucrose overnight, duodenal biopsies were blotted dry, transferred to optimal cutting temperature (OCT) embedding medium, slowly frozen using liquid nitrogen, and then stored at Ϫ80°C until analysis. Tissues were sectioned at 8 m using a cryostat (CM 1950; Leica Microsystems, Wetzlar, Germany) and thaw mounted directly onto gelatin-coated microscope slides. Double-label immunohistochemistry was then performed on sections. Antibodies to GPR40, GPR120, GPR119, and CD36 were coincubated with antibodies to CCK or GLP-1 (see Table 3 for antibody information and dilutions).
FA-sensing GPRs and CCK or GLP-1. Primary antibodies to GPR40, GPR120, and GPR119 were visualized using chicken anti-rabbit secondary antibody conjugated to Alexa Fluor 488 (Life Technologies). Primary antibodies to CCK and GLP-1 were visualized using chicken anti-goat secondary antibody conjugated to Alexa Fluor 647 (Life Technologies). Briefly, sections were air dried at room temperature and rinsed in Tris-buffered saline (ϫ1) ϩ 0.2% Tween 20 (TBST, pH 7.4; Sigma-Aldrich) and then subjected to an antigen retrieval step using DAKO Target Retrieval Solution (DAKO Australia, North Sydney, NSW, Australia) for 10 min at 95°C and then 10 min at room temperature to facilitate antibody penetration. Slides were subsequently washed in TBST and blocked using 5% chicken sera (Life Technologies) in TBST for 60 min. Primary antibodies were diluted in TBST and incubated at 4°C overnight. Unbound antibody was then removed with TBST washes, and sections were incubated for 1 h at room temperature with species-specific Alexa Fluor conjugated secondary antibodies (1:200 in TBST). The sections were given final TBST washes, drained, and mounted with ProLong Gold Antifade (Life Technologies). Slides where the primary antibodies were omitted showed no labeling and served as negative controls. CD36 and CCK. Monoclonal antibody to CD36 was coincubated with CCK. CD36 was visualized using chicken antimouse secondary antibody conjugated to Alexa Fluor 488 (Life Technologies). CCK was visualized using chicken anti-goat secondary antibody conjugated to Alexa Fluor 594 (Life Technologies). Briefly, sections were air dried at room temperature and rinsed in TBST (pH 7.4; Sigma-Aldrich), subsequently blocked using 5% chicken sera (Life Technologies) in TBST for 60 min. CD36 antibody was diluted in TBST and incubated at 4°C overnight. Unbound antibody was removed with TBST washes, and sections were incubated for 1 h at room temperature with anti-mouse secondary antibody conjugated to Alexa
Visualization of Immunolabeled Slides
Sections were visualized using an epifluorescence microscope (BX-51; Olympus) equipped with filters for Alexa Fluor 488, 594, and 647, with images acquired by a Cool-Snapfx monochrome digital camera (Roper Scientific). Individual fluorochromes were pseudocolored using Olympus Imaging analysis software; however, luminance of images was not adjusted. Fig. 1 . Absolute levels of cluster of differentiation (CD)36, G protein-coupled receptor (GPR)40, GPR120, and GPR119 transcript in human duodenal mucosal biopsies from lean (n ϭ 9), overweight (n ϭ 6), and obese (n ϭ 7) individuals. In all groups, CD36 was expressed more abundantly than the GPRs, GPR40 was more abundant than GPR120, and GPR120 was more abundant than GPR119 (P Ͻ 0.05, for all). Data are means values Ϯ SE. 
Quantification of Labeled Enteroendocrine Cells
CCK-expressing I cells or GLP-1-expressing L cells were identified, and the filters were then switched to determine whether the same EECs also expressed the second fluorescently labeled antigen (i.e., CD36, GPR40, GPR120, or GPR119). Total numbers of both individual labeled and double-labeled cells were counted for each duodenal biopsy section, with a total of 8 -10 sections counted for each subject. Section area was measured for each subject, and counts were adjusted and expressed per millimeter squared of tissue area. Only five obese subjects were included in this analysis because biopsies from two obese subjects contained artifacts from processing.
Habitual Dietary Intake
Following the endoscopy, participants completed a food frequency questionnaire to assess their average dietary intake over the last 12 mo (DQES v2; Cancer Council Victoria, Carlton, Victoria, Australia; Ref. 10 ). This questionnaire has been validated specifically for use in Australian adults (15) .
Statistical Analysis
One-way ANOVA, followed by post hoc testing (Bonferroni adjusted), was performed to evaluate differences in transcript levels between the FA-sensing receptors within each group. Following inspection of scatter plots, linear relationships among transcript levels, BMI, age, and dietary [energy (kcal) and fat (g)] intake were assessed using Pearson correlations, providing a Pearson correlation coefficient (r). However, for GPR119, relationships with BMI were estimated using curve estimation, with an inverse curve fitted to the data, giving an r 2 value. Statistical analysis was performed using GraphPad Prism Version 6.02 for Windows (GraphPad Software, La Jolla, CA; www.graphpad.com) and IBM SPSS Statistics Version 21. Data are expressed as means Ϯ SE. Statistical significance was accepted at P Ͻ 0.05.
RESULTS
Expression of the FA-Sensing Receptors CD36, GPR40, GPR120, and GPR119 in the Human Duodenum
qRT-PCR analysis demonstrated the presence of transcripts for the FA-sensing receptors CD36, GPR40, GPR120, and GPR119 in human duodenal mucosal biopsies (Fig. 1) . Comparison of absolute transcript levels within each group (lean, overweight, and obese) demonstrated that CD36 was the most abundantly expressed, while GPR40 was more abundant than GPR120 and GPR119 (P Ͻ 0.01, for each in all groups). GPR120 expression was more abundant than GPR119 (P Ͻ 0.01 in all groups).
Relationships Between Duodenal FA-Sensing Transcript Levels with BMI
There were direct correlations between absolute transcript levels of GPR120 (r ϭ 0.46, P ϭ 0.03), and CD36 (r ϭ 0.69, P ϭ 0.0004), with BMI ( Fig. 2) , such that transcript levels of GPR120 and CD36 increased with increasing BMI. There was an inverse correlation between expression of GPR119 with BMI (r 2 ϭ 0.26, P ϭ 0.016). There was no correlation between expression of GPR40 with BMI. No correlations were found between FA-sensing receptor expression and gender or age.
Immunolabeling
Immunolabeling with primary antibodies for GPR40, GPR120, and GPR119 identified populations of solitary epithelial cells in the duodenum. These cells were present throughout the duodenal mucosa and were of the open cell type (enteroendocrine cells), with the apical end accessible to the lumen (Fig. 3, C-E) . CD36 immunolabeling was present at the brush border membrane of all epithelial cells, except for goblet cells (Fig. 3F) .
Dual-immunolabeling revealed that subsets of cells expressing GPR40, GPR120, and GPR119 contained GLP-1 and CCK (Fig. 4) and that CD36 was localized at the brush border membrane of cells positively immunolabeled with CCK (Fig. 5) . In Table 4 , we present the percentage of cells per millimeter squared that colabeled for each of the GPRs and either CCK or GLP-1 in lean, overweight, and obese participants. In Table 5 , we present the percentage of CCK or GLP-1 cells per millimeter squared that colabeled with GPR40, GPR119, or GPR120. The frequency of colabeling was variable between markers, and was not complete. For example, while ϳ90% of the cells immunolabeled with GPR120 colabeled with GLP-1, only 14 -50% of the cells immunolabeled with GLP-1 colabeled with GPR120. Furthermore, as CD36 labeled the entire brush border membrane, we were unable to quantify CD36-immunopositive cells using the counting technique applied to the other markers.
There were inverse correlations between the number of cells per millimeter squared immunolabeled with CCK (r ϭ Ϫ0.49, P ϭ 0.045) and GLP-1 (r ϭ Ϫ0.54, P ϭ 0.003) with BMI ( Fig. 6) , such that duodenal CCK and GLP-1 cell density significantly decreased with increasing BMI. There were no correlations between the number of cells millimeter squared immunolabeled with GPR40, GPR120, and GPR119 with BMI.
Habitual Dietary Intake
Energy and fat intakes are reported in Table 6 . GPR120 mRNA expression correlated with energy intake (kcal; r ϭ 0.43, P ϭ 0.04), and there was a trend for a correlation with fat intake (g; r ϭ 0.41, P ϭ 0.055). There were no other significant correlations between dietary intakes with transcript levels of the FA-sensing receptors CD36, GPR119, or GPR40, or with the number of cells immunolabeled with CCK, GLP-1, GPR40, GPR119, and GPR120.
DISCUSSION
This study has established that the FA receptors CD36, GPR40, GPR120, and GPR119 are expressed in the duodenum of humans. Immunolabeling revealed localization of CD36 on the brush border membrane of the duodenal mucosa and of the GPRs on CCK-expressing I cells and GLP-1-expressing L cells. Hence, the human duodenum is equipped with a broad range of mechanisms to sense ingested dietary fat. This study also provides the first evidence that intestinal FA-sensing mechanisms are altered with increasing BMI. FA-receptor transcripts for CD36 and GPR120 were increased, and those for GPR119 decreased, with increasing BMI. Furthermore, the number of cells immunoreactive for CCK and GLP-1 was decreased with increasing BMI. Taken together, altered expression of FA-receptor transcripts, coupled with reduced numbers of I and L cells, may underlie the decreased GI hormone responses to fat and impaired regulation of energy intake that have previously been reported in obesity (33) . The expression of GPR120 was also found to correlate with energy intake, suggesting that changes in FA-sensing may be driven by habitual dietary patterns.
Our results are, to our knowledge, the first to describe expression of GPR40 transcript in human duodenum and confirm previous reports of mRNA expression of CD36 (24), GPR119 (26) , and GPR120 (32) . By using absolute quantification, we were able to establish that transcript levels of CD36 were substantially more abundant than the GPR transcript levels, consistent with its established role as a FA transporter in the duodenal mucosa (24) . The higher absolute transcript levels of GPR40, relative to GPR120 and GPR119, imply an important role for GPR40 in FA sensing and signaling in the proximal small intestine. This proposition is supported by previous studies demonstrating the involvement of GPR40 in FA-mediated CCK secretion from I cells (20) , which are located predominantly in this region. It has also been demonstrated recently that CD36, expressed most abundantly in the proximal small intestine, plays an important role in the regulation of CCK secretion (34) . In contrast, GPR120 and GPR119 have been implicated more strongly in the regulation of gut hormone secretion from L cells, which increase in 
Data are mean values Ϯ SE. Lean: n ϭ 7; overweight: n ϭ 5; obese: n ϭ 5. Table 5 .
Percentage of duodenal cells immunopositive for CCK or GLP-1 that co-labeled for GPR40, GPR119, or GPR120
Data are mean values Ϯ SE. OW, overweight. Lean: n ϭ 7; overweight: n ϭ 5; obese: n ϭ 5. number towards the distal small intestine (14, 16, 17) . However, it should be noted that we counted a significant number of GLP-1-immunolabeled cells in the human duodenum, consistent with previous reports (36) . When examining localization, we confirmed previous reports that CD36 is found in the brush border membrane of the duodenal mucosa (24) , while demonstrating that in humans, immunolabeling for the GPRs was limited to enteroendocrine cells. In the human duodenum, it appears that there is a strong overlap of the FA-sensing GPRs expressed in different types of EECs, with GPR40, GPR120, and GPR119, all demonstrating some level of colocalization with CCK and GLP-1 (albeit with minimal overlap between CCK and GPR40), suggesting that different EEC classes express common nutrient-sensing machinery. However, it must be noted that the percentage of cells demonstrating colabeling, except for GLP-1 ϩ GPR120, was generally low in the fasting state. It is not known whether the expression and localization of these receptors are rapidly altered following ingestion of a meal; this issue requires further investigation. It is also possible, for example, that GPR40 may localize to other EEC types in the human duodenum. In support, it has been reported that the release of glucosedependent insulinotropic polypeptide (GIP) in response to fat intake in mice is diminished in GPR40-null mutants (6) . Furthermore, recent studies have demonstrated considerable overlap in hormone expression among I, K, and L cells, suggesting that they may represent a single cell type that is tuned to secrete specific hormones depending on their location and exposure to specific dietary components (13) . Further work is required to determine the expression of these molecules in other EEC types, the downstream signaling pathways activated by binding of FAs to these receptors, how EEC distribution and nutrient-sensing mechanisms are altered by dietary status (e.g., fasting vs. fed state), and their specific role(s) in the release of GI hormones in humans.
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We also demonstrated colabeling of CCK and CD36 in individual epithelial cells, with CD36 expressed at the brush border membrane and CCK expressed at the basolateral aspect of the cell. However, in contrast to the studies of Sundaresan et al. (34) , there was no cytoplasmic labeling evident for CD36. This may be due to species differences or to the different antibodies employed. We did not evaluate the localization of CD36 with other gut hormones; however, given the consistent labeling of CD36 across the entire brush border, it would seem likely that a similar pattern of labeling would occur on other enteroendocrine cell types as well. This is an issue that requires further study.
This study also examined whether obesity (increased BMI) was associated with altered duodenal expression of FA-sensing mechanisms. The underlying rationale was our previous observation that obese individuals have impaired CCK and GI motility responses to intraduodenal C18:1 and, consequently, consume a greater amount of energy at a subsequent meal (33) , as well as extensive data from animal studies demonstrating attenuated GI function and energy intake suppression in response to fat following high-fat-diet exposure (4). In the current study, we were able to demonstrate that transcript levels of CD36, GPR120, and GPR119 and immunolabeling for CCK and GLP-1 correlated with BMI. These observations are consistent with the concept that altered expression of FA-sensing receptors, and decreased numbers of EECs, may contribute to the decreased secretion of GI hormones observed in obesity. Future work will need to investigate the direct relationship between FA-receptor expression and GI peptide responses to fat in humans.
Importantly, we demonstrated a positive correlation between transcript levels of GPR120 habitual energy intake (as well as a strong trend for a relationship with fat intake). This is consistent with studies of GPR120 expression in a rat model of high-fat-diet-induced obesity (DIO). High-fat DIO rats have increased transcript and protein levels for GPR120 and GPR40 in the proximal small intestine but decreased CCK, PYY, and GLP-1 protein expression relative to DIO-resistant (DIO-R) rats (5) . We also observed a decrease in the number of cells immunolabeled with CCK and GLP-1 in obese humans. These results implicate altered transcript and protein expression of FA-sensing receptors and gut hormones in the pathophysiology of obesity. Indeed, GPR120-knockout mice fed a high-fat diet are known to develop obesity, glucose intolerance, and insulin resistance (16) . These observations suggest an important role for GPR120 in mediating the GI response to dietary fat and a potential role for impaired GPR120 activation/signaling in the pathophysiology of obesity. Further work is required to determine whether such changes in FA-receptor expression are driven by diet (e.g., chronic consumption of a high-fat diet) or whether altered GPR120 (and other FA-sensing receptors) itself predisposes to the development of obesity. The latter concept is supported by recent studies that have identified a polymorphism in GPR120 (R270H variant) that is associated with increased risk of obesity and insulin resistance (16) . Furthermore, long chain FA-induced GLP-1 release from human intestinal NCI-H716 cells has been shown to be attenuated when the cells were transfected with the R270H variant (16) . It is well established in animal models that a high-fat diet leads to the proliferation of small intestinal cells, increased secretion of pancreatic lipase (31) , and increased intestinal absorption of C18:1 (29) , and there is evidence that this may be mediated, at least in part, by upregulation of CD36 mRNA expression, apparent after only 3 days on a high-fat diet (27) . To date, studies have not evaluated the effects of acute or chronic nutrient exposure on FA-receptor expression in humans. Our observation of increased CD36 expression may indicate that increased fat intake in obesity may upregulate CD36 to facilitate increased fat absorption. While in the current study we did not find a relationship between dietary fat intake and CD36 transcript levels, or statistically significant increases in energy or fat consumption in the obese, this may represent a type 2 statistical error due to the relatively small sample size and high variability in reported intakes in all groups but particularly the obese. It is also important to note that subjects, especially the obese, tend to underreport dietary intake, particularly for fat (2, 12) . Furthermore, the questionnaire we used to measure dietary intakes has been validated for the quantification of average food intake over the previous 12 mo and, thus, may not accurately reflect participants' recent fat consumption before the study. Thus it is conceivable that the actual fat intake was higher and that inaccurate reporting may have influenced our results. Further work is needed to clarify the role of diet composition in mediating intestinal fat sensing.
A number of limitations of our study warrant discussion. The study was undertaken in a restricted number of obese participants due to the limitation of recruiting through the endoscopy clinic those who met our strict criteria; hence, the results may be considered preliminary. We cannot exclude that the observed differences between obese and nonobese may be due to the very high BMIs of some of the obese subjects; thus future studies will need to be conducted across a broader range of obese BMIs and include larger cohorts. Moreover, participants were undergoing surveillance or therapeutic endoscopy; thus, despite their normal mucosal histology, it is unclear whether they truly represent the healthy population. We also demonstrated that the biopsies collected from individuals with a greater BMI had a lower number of enteroendocrine cells immunolabeled with CCK and GLP-1 per millimeter squared. Hence, altered GPR transcript levels may reflect this discrepancy in enteroendocrine cell number; this issue will need to be investigated in further detail in future studies. However, we believe that this is an important observation, since decreased cell number, coupled with decreased receptor expression, is likely to represent decreased enteroendocrine signaling capacity in the obese. We obtained biopsies from the duodenum in the fasting state; therefore, it will be important to determine whether expression is differentially regulated by nutrient exposure in lean and obese individuals. Moreover, FA-receptor expression in other regions of the gut, e.g., the jejunum and ileum where L cell density is greater, also requires investigation. Finally, there was a substantial degree of interindividual variability, even within the lean group, for a number of variables, including self-reported fat and energy intake, and expression of GPR119 was far more variable in healthy individuals than GPR120 and GPR40. It is possible that this is related to different dietary patterns or gene polymorphisms; thus future studies are required to determine the relationship between receptor expression with gut hormone secretion and the control of energy intake.
In summary, this study provides the first evidence that FA-receptor transcripts and immunoreactive cells are altered in the duodenum of obese humans. This change, together with reduced numbers of EECs, may underlie decreased GI hormone responses to fat and impaired regulation of energy intake in obesity. Further studies are now required to characterize how dietary fat regulates the expression of FA-sensing mechanisms within the small intestine in health and obesity and the role of these receptors in the regulation of GI hormone secretion and food intake. Such knowledge may provide a basis for targeted therapeutic approaches to the management of obesity and its comorbidities.
